Vistagen Therapeutics, Inc. (VTGN) stock
VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3073% below fair value
$0.18+0.00 (+0.95%)
Close on Nov 13, 2026Market cap $8.01MP/E –Yield –
Vistagen Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Vistagen Therapeutics's enterprise value was -$24.03M on Nov 11, 2026, against $81.99M a year earlier. Over the last 5 years it ranged from -$61.44M to $203.88M, with a median of -$10.07M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$24.03M | – |
| 2025 | Dec 31, 2025 | -$55.70M | – |
| 2024 | Dec 31, 2024 | -$8.26M | -396.0% |
| 2023 | Dec 29, 2023 | $2.79M | – |
| 2022 | Dec 30, 2022 | -$14.73M | -107.2% |
| 2021 | Dec 31, 2021 | $203.88M | +137.4% |
| 2020 | Dec 31, 2020 | $85.90M | +290.9% |
| 2019 | Dec 31, 2019 | $21.98M | -9.4% |
| 2018 | Dec 31, 2018 | $24.26M | +195.9% |
| 2017 | Dec 29, 2017 | $8.20M | +2325.9% |
| 2016 | Dec 30, 2016 | $338.05K | -97.6% |
| 2015 | Dec 31, 2015 | $13.89M | +28.8% |
| 2014 | Dec 31, 2014 | $10.79M | +24.9% |
| 2013 | Dec 31, 2013 | $8.64M | -28.8% |
| 2012 | Dec 31, 2012 | $12.13M | -73.9% |
| 2011 | Dec 30, 2011 | $46.39M | – |
See a number that looks wrong?